STERIS plc STE revenue by segment, product and geography
In its fiscal year ending 2026-03-31, STERIS plc reported revenue across 3 business segments; the largest, Healthcare Segment, was $4.21B, 70.9% of the filed sum (+8.5% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Healthcare Segment$4.21B70.9%+8.5% yoy
- Applied Sterilization Technologies$1.14B19.2%+9.6% yoy
- Life Science$589M9.9%+8.6% yoy
Members sum to the consolidated $5.94B for this period.
- Product$3.06B51.6%+6.6% yoy
- Service$2.88B48.4%+11.1% yoy
Members sum to the consolidated $5.94B for this period.
- United States$4.33B73.0%+8.1% yoy
- Otherforeignlocations$1.49B25.2%+11.1% yoy
- Ireland$109M1.8%+1.1% yoy
Members sum to the consolidated $5.94B for this period.
- Healthcare Segment$1.06B71.1%+9.0% yoy
- Applied Sterilization Technologies$287M19.2%+11.0% yoy
- Life Science$146M9.7%+6.9% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.